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Abstract
Background:  Asthma is a complex disease, characterized by reversible airway obstruction,
hyperresponsiveness and chronic inflammation. Principle pharmacologic treatments for asthma
include bronchodilating beta2-agonists and anti-inflammatory glucocorticosteroids; but these
agents do not target the main cause of the disease, the generation of pathogenic Th2 cells. We
previously reported reduction in allergic inflammation in mice deficient in the ANP receptor NPRA.
Here we determined whether siRNA for natriuretic peptide receptor A (siNPRA) protected
against asthma when administered transdermally.
Methods: Imiquimod cream mixed with chitosan nanoparticles containing either siRNA green
indicator (siGLO) or siNPRA was applied to the skin of mice. Delivery of siGLO was confirmed by
fluorescence microscopy. The anti-inflammatory activity of transdermal siNPRA was tested in
OVA-sensitized mice by measuring airway hyperresponsiveness, eosinophilia, lung histopathology
and pro-inflammatory cytokines.
Results: SiGLO appearing in the lung proved the feasibility of transdermal delivery. In a mouse
asthma model, BALB/c mice treated with imiquimod cream containing siNPRA chitosan
nanoparticles showed significantly reduced airway hyperresponsiveness, eosinophilia, lung
histopathology and pro-inflammatory cytokines IL-4 and IL-5 in lung homogenates compared to
controls.
Conclusion: These results demonstrate that topical cream containing imiquimod and siNPRA
nanoparticles exerts an anti-inflammatory effect and may provide a new and simple therapy for
asthma.
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Introduction
Chitosan is a natural cationic polysaccharide extracted
from crustacean shells. It is a good candidate for the deliv-
ery of genes and drugs because of its biodegradability, bio-
compatibility, mucoadhesiveness, low immunogenicity,
and strong immunostimulatory properties [1-3]. It has
been found to have beneficial properties including antico-
agulant, wound-healing and anti-microbial activities.
Chitosan has also been widely used in controlled drug
delivery [4-7] because it is nontoxic, nonhemolytic,
slowly biodegradable and capable of encapsulating a drug
or DNA to protect it from enzymatic degradation. The
interaction between cationic amino groups on chitosan
and anionic moieties such as sulfonic acid on the mucus
layer enhances its muco-adhesiveness. Furthermore, chi-
tosan is known to cross the epithelial barrier through tight
junctions [8]. We have reported on chitosan delivery of
vector-driven small interfering RNA (siRNA) intranasally
to protect mice from respiratory syncytial virus infection
[3].
While oral and intranasal routes of drug delivery are com-
monly used, each of these routes has its limitations. For
example, orally delivered drugs have to undergo first-pass
metabolism which can rapidly inactivate them. The nasal
route may be inadequate for infants and children with
congested noses due to allergy or infection. Transdermal
delivery may be the ideal modality because skin is the
most accessible organ of the body and the route with the
highest therapeutic compliance; but for transdermal entry
of DNA only liposomes and polymers have had limited
success [9-11].
Since the size of the sweat pores and the follicular open-
ings of the skin are 30 to 100 μm, it is reasonable to expect
that nanocomplexes would facilitate the penetration
through the skin of DNA or small oligonucleotides such
as siRNAs [12]. siRNAs have become a powerful tool for
gene silencing and have the potential to become the pre-
ferred form of treatment for cancer and infectious disease.
The combination of gene-silencing through siRNA with
the greatly enhanced delivery offered by nanoparticles
provides a therapeutic system with a high degree of flexi-
bility, specificity and safety. Previously, cationic lipids
were reported to successfully deliver siRNA across
mucosal surfaces [13,14]. In this report, we developed and
tested a topical siRNA delivery system based on chitosan
nanoparticles. The natriuretic peptide receptor A (NPRA)
was selected as the siRNA target because it was recently
found that NPRA knockout prevented lung inflammation
in a mouse model of allergic asthma. NPRA is the primary
receptor for atrial natriuretic peptide (ANP), which has
been associated with allergic inflammation and asthma.
NPRA is expressed on cells in many different tissues of var-
ious organ systems and the cell-surface receptor contains
an intrinsic guanylyl cyclase that is activated by ANP bind-
ing. ANP signals primarily through NPRA by increasing
cGMP and activating cGMP-dependent protein kinase
(PKG). Activated PKG turns on ion transporters and tran-
scription factors, which together affect cell growth and
proliferation, and inflammation [15].
To test whether topical delivery of siRNA for NPRA can
reduce chronic inflammation of the lung in an experimen-
tal asthma model, 5% imiquimod cream was mixed with
siNPRA nanoparticles. Imiquimod cream has two advan-
tages in our test: first, imiquimod itself has been reported
to modulate airway inflammation [16,17] when given
intranasally; secondly, the cream contains the penetrating
agent polysorbate 60 [18] which facilitates the penetra-
tion siRNA nanoparticles through the skin. Imiquimod, as
a TLR-7 agonist, was reported to have Th1-biased immune
responses by increasing TNF-α and IL-12 in dendritic cells
[19]. By combining the treatment of imiquimod and siN-
PRA nanoparticles, we anticipated that more protection
against airway inflammation would be achieved in a
mouse model of asthma.
Materials and Methods
Cell lines
The HEK293 cell line was purchased from ATCC (Rock-
ville, MD) and the human prostate cancer cell line PC3
was kindly provided by Dr. Wenlong Bai at the University
of South Florida. All three cell lines were grown in Earle's
modified Eagle's medium supplemented with 10% fetal
bovine serum at 37°C in a 5% CO2 incubator. HEK-GCA,
a stable cell line overexpressing NPRA, was established in
our lab. HEK-GCA was grown in Dulbecco's modified
Eagle's medium with 10% fetal bovine serum and 1 μg/ml
hygromycin.
SiRNA: siGLO and siNPRAs
As siRNA marker, siGLO green indicator was purchased
from Dharmacon Research Inc. For siRNA against NPRA,
several targeting sequences were located using siRNA
finder software (Ambion, Austin, TX). Vector-driven siN-
PRA were constructed by cloning the annealed siNPRA
oligonucleotide primers between the Apa I and EcoR I sites
of pSilencer-1.0 (Ambion, Austin, TX). The resulting siN-
PRA plasmids were used to transfect HEK-GCA cells.
Thirty six hours after transfection, cells were harvested and
cell lysates subjected to Western blot assay to determine
which siNPRA construct gave the best inhibition in NPRA
expression. Each siNPRA construct was also given to mice
intranasally to confirm its effectiveness. The most effective
siNPRA we tested has the sequence: GGGCGCUGCUGC
UGCUACCdTdT (sense). The scrambled siRNA is a ran-
dom rearrangement of the normal siNPRA with the
sequence CGUCGAGUGCCGUCGUGCCdTdT. The syn-
thetic siNPRA was prepared by annealing the sense siN-Genetic Vaccines and Therapy 2008, 6:7 http://www.gvt-journal.com/content/6/1/7
Page 3 of 9
(page number not for citation purposes)
PRA oligonucleotide strand and the antisense strand by
following the instructions of Integrated DNA Technolo-
gies, Inc. (Coralville, IA).
Animals
Female BALB/c and nude mice, 6–8 weeks of age, were
purchased from Jackson Laboratory (Bar Harbor, ME).
NPRA-/- C57BL/6 mice were kindly provided by Dr. Wil-
liam Gower at the University of South Florida. All mice
were maintained in a pathogen-free environment, and all
procedures were reviewed and approved by the University
of South Florida Institutional Committee on Animal
Research. Mice were tested for siNPRA efficacy in blocking
NPRA expression first, and then for protection against air-
way inflammation in an ovalbumin sensitization and
challenge model.
Preparation and characterization of siRNA 
chitosannanoparticles
Preparation and characterization of siRNA chitosan nano-
particles was performed as previously described [5].
Briefly, chitosan (33 kDa, with 90% deacetylation) was
obtained from TaeHoon Bio (Korea). Chitosan stock solu-
tion (10 mg/ml) was prepared in 1% acetic acid. siGLO,
siNRNA or pEGFP-N2 plasmid DNA were mixed with chi-
tosan at a ratio of 1:5 (wgt:wgt). After chitosan was added
to the diluted DNA or siRNA solution, the mixture was
vortexed vigorously for 20–30 sec and stored at room tem-
perature until use. For transfection of siGLO and pEGFP-
N2, HEK293 cells were grown on 6-well plates were incu-
bated with chitosan nanoparticles containing 200 pmol of
siGLO or 1 ug of pEGFP-N2. Eight hours later the cells
were washed with PBS and recultured in regular medium.
However, lipofectamine 2000 (Invitrogen, CA) was used
to transfect siNPRA into HEK-GCA cells to evaluate the
inhibition of NPRA expression by siNPRA though West-
ern blot assay. For topical administration of siGLO or siN-
PRA to the back of each mouse, 2 nmol of siGLO or 5
nmol of siNPRA were complexed with 50 μg or 125 μg of
chitosan, respectively, before mixing with imiquimod
cream. Intranasally delivered pEGFP-N2 was selected as a
positive control for whole-body fluorescence imaging. In
this assay, 25 μg of pEGFP-N2 was complexed with 125 μg
of chitosan and vortexed for 20 minutes before being
given to mice as nasal drops.
Western blots
HEK-GCA cells were grown in 6-well plates and trans-
fected with 200 pmol of siNPRA or scrambled siRNA (Scr)
using Lipofectamine 2000 according to the manufac-
turer's instructions (Invitrogen, CA). To extract whole-cell
protein, cells were harvested 48 h after transfection and
resuspended in lysis buffer containing 50 mM HEPES, 150
mM NaCl, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 0.5%
NP-40, 0.1 mM phenylmethylsulfonyl fluoride, 2.5 μg/ml
leupeptin, 0.5 mM NaF, and 0.1 mM sodium vanadate.
Fifty μg of protein was subjected to sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis on a 10% polyacr-
ylamide gel and then transferred onto nitrocellulose
membranes. Western blot assay was performed according
to the manufacturer's instructions (Cell Signaling Tech-
nology, Beverly, MA).
Modulation of lung inflammation by siNPRA
Sixteen BALB/c mice were divided into four groups (n = 4
per group). One group served as naïve control with no
OVA sensitization or challenge and no siRNA nanoparti-
cle treatment. The second group received OVA sensitiza-
tion (50 μg OVA i.p. injected on day 1 and day 7) and
OVA challenge (25 μg intranasally on day 18, 19, 20 and
21). Animals in the third group got OVA sensitization,
Ova challenge and transdermal treatment with siNPRA
nanoparticles (containing 5 nmol of siNPRA on day 18,
19, 20, and 21). The last group was OVA-sensitized and –
challenged, but treated with scrambled siRNA nanoparti-
cles (containing 5 nmol of siNPRA on day 18, 19, 20 and
21). To prepare siNPRA nanoparticles, synthetic siNPRA
was complexed with chitosan by mixing 5 nmol of siN-
PRA with 150 μg of chitosan polymers. The chitosan and
siNPRA mixture was vortexed vigorously for 30 seconds
and stored at room temperature until use. SiNPRA nano-
particles were given to mice intranasally or transdermally.
When given transdermally, siNPRA nanoparticles con-
taining 5 nmol of siNPRA were mixed with 62.5 mg of 5%
imiquimod cream (3 M pharmaceuticals, Northridge, CA)
which contains the penetrating agent polysorbate 60 and
applied to shaved skin on the backs (above the lung) of
the BALB/c mice. A control group received the same
amount of scrambled siRNA nanoparticles mixed with
imiquimod cream. All mice were sacrificed to collect BAL
fluid. Mouse lungs were rinsed with intratracheal injec-
tions of PBS then perfused with 10% neutral buffered for-
malin. Lungs were removed, paraffin-embedded,
sectioned at 20 μm, stained with hematoxylin and eosin
(H & E) and examined under the microscope to determine
lung pathology.
Differential cell enumeration in bronchoalveolar 
lavagefluid
Bronchoalveolar lavage (BAL) fluid was collected and dif-
ferential cell counts were performed as previously
described [7]. Briefly, BAL was centrifuged and the cell
pellet was suspended in 200 μl of PBS and counted using
a hemocytometer. The cell suspensions were then centri-
fuged onto glass slides using a cytospin centrifuge at 1000
rpm for 5 min at room temperature. Cytocentrifuged cells
were air dried and stained with a modified Wright's stain
(Leukostat, Fisher Scientific, Atlanta, GA) which allows
differential counting of monocytes and lymphocytes. AtGenetic Vaccines and Therapy 2008, 6:7 http://www.gvt-journal.com/content/6/1/7
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least 300 cells per sample were counted by direct micro-
scopic observation.
Determination of airway hyperreactivity (AHR)
AHR, expressed as enhanced pause (Penh), was measured
in unrestrained mice by whole body plethysmography
(Buxco, Troy, NY). Groups of mice (n = 4) were exposed
for 5 min to nebulized PBS to establish a baseline then to
increasing concentrations (6–25 mg/ml) of nebulized
methacholine (MCh; Sigma, St. Louis, MO) in PBS. Chal-
lenges were done for 5 min followed by recordings of
Penh for 5 min. The Penh values were averaged and
expressed for each MCh concentration as a percentage of
the baseline reading.
Statistics
A minimum of four mice was used in each test group.
Experiments were repeated at least once and measure-
ments were expressed as means plus or minus standard
error of the mean or standard deviation. Comparisons of
groups were done using a two-tailed Student's t test and p
< 0.05 was considered significant.
Results
Transdermal delivery of siGLO using chitosan 
nanoparticles
First, we tested if chitosan polymers can help to transfect
cells with siRNA in vitro using siGLO as a fluorescent
siRNA marker [20]. To prepare siGLO-chitosan nanopar-
ticles, 0.2 nmol of siGLO were complexed with 5 mg of
chitosan polymers (33 kDa) before transfection. HEK293
cells were transfected and the incorporation of siGLO into
HEK293 cells was monitored by fluorescence microscopy
24–48 hrs after transfection (Fig. 1A). HEK293 cells were
also transfected with pEGFP-N2 chitosan nanoparticles as
a positive control (Fig. 1A). Next, lung sections were pre-
pared from siGLO-treated mice and the presence of siGLO
in the lung was confirmed by fluorescence microscopy
(Fig. 1B). We also tested if chitosan nanoparticles could
deliver siGLO transdermally in mice. SiGLO chitosan nan-
oparticles (2 nmol siGLO plus 50 mg of chitosan) were
mixed with 62.5 mg of 5% imiquimod cream and applied
to the backs of BALB/c nude mice. A second application
was done at the same location 24 hrs later. Distribution of
siGLO in vivo was detected through whole-body fluores-
cence imaging using a Xenogen IVIS system. SiGLO was
found to reach the lung 48 hrs after treatment (Fig. 1C).
Intranasally-delivered pEGFP-N2 nanoparticles (without
cream) were included as a positive control for the pres-
ence of fluorescence (Fig. 1A–C).
NPRA deficiency reduced lung inflammation in a mouse 
asthma model
Current pharmacologic treatments for asthma act only on
symptoms and do not target the main cause of the disease,
the generation of pathogenic Th2 cells [21-23]. Hence,
there is a continued search for new therapeutic agents
against allergy and asthma. Since plasma ANP levels have
been shown to increase during asthma exacerbation [18],
we used mice deficient in the receptor for ANP (NPRA-/-)
to examine the role of the ANP pathway in lung inflam-
mation and asthma. In the mouse model of asthma,
C57BL/6 wild type, NPRA-/- and NPRC-/- knockout mice
were sensitized intraperitoneally (i.p.) with ovalbumin
(OVA), the allergen used in the mouse model of allergic
asthma, and then challenged with OVA intranasally (i.n.).
NPRA-/- mice mounted little inflammatory response, as
evidenced by the lack of goblet cell hyperplasia and
decreased numbers of cells infiltrating the lungs (Fig. 2A).
On the other hand, NPRC-/- mice that lack the ANP clear-
ance receptor, NPRC, showed pathological effects similar
to WT. Bronchoalveolar lavage (BAL) fluid from NPRA-/-
mice had reduced levels of the inflammatory cytokines,
IL-4, IL-5 and IL-6, relative to wild type (Fig. 2B). From
this result we reasoned that inhibition of ANP-NPRA sig-
naling by siRNA against NPRA might be protective against
airway inflammation and asthma.
Selection of synthetic siNPRAs effective against NPRA
To test if transdermal siRNA nanoparticles can attenuate
lung inflammation and asthma, we constructed three vec-
tor-driven siNPRAs targeting different regions of the
human NPRA coding sequence. Inhibition of NPRA
expression by different constructs was measured by West-
ern blot assay. Based on their knockdown efficiency, we
synthesized two siNPRA primers with sense strand
sequence GGGCGCUGCUGCUGCUACCdTdT, and anti-
sense strand GGUAGCAGCAGCAGCGCCCdTdT. Func-
tional siNPRA was obtained by annealing the primers. As
a control, a scrambled siRNA was also prepared. When
synthetic siNPRA (0.1 nmol) was transfected into HEK-
GCA cells, NPRA expression was significantly reduced
compared to untreated controls or cells treated with
scrambled siRNA (data not shown).
Treatment with siNPRA and imiquimod cream decreased 
airway hyperresponsiveness
Topical treatment with siNPRA nanoparticle in imiqui-
mod cream was tested to determine if it could attenuate
airway inflammation. Several clinical parameters of
asthma and biological markers of airway inflammation
were evaluated. Four groups (4 mice per group, back hair
shaved) of BALB/c mice were tested. The first group served
as naive control while the second group received OVA sen-
sitization and OVA challenge as the positive control. Ani-
mals in the third group got siNPRA treatment as well as
OVA sensitization/challenge, while the last group was
OVA-sensitized and – challenged, but treated with scram-
bled siNPRA nanoparticles. Airway hyperresponsiveness
(AHR) to aerosol methacholine challenge (6.25 to 25 mg/Genetic Vaccines and Therapy 2008, 6:7 http://www.gvt-journal.com/content/6/1/7
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Delivery of siGLO chitosan nanoparticles in vitro and in vivo Figure 1
Delivery of siGLO chitosan nanoparticles in vitro and in vivo. (A) HEK293 cells were transfected with 200 pmol of 
siGLO complexed with 5 μg of chitosan nanoparticles. Fluorescent cells containing siGLO were observed by fluorescence 
microscopy. HEK293 cells were also transfected with chitosan nanoparticles containing green fluorescent protein expression 
plasmid, pEGFP-N2, as a positive control. (B) The green fluorescence from the frozen lung sections of mice treated transder-
mally with siGLO or intranasal pEGFP-N2 nanoparticles was monitored by fluorescence microscopy. (C) siGLO nanoparticle 
cream containing 2 nmol of siGLO was spread on the backs of BALB/c nude mice, and a second dose of siGLO nanoparticles 
was administered 24 h later. The transdermally-delivered siGLO was detected 48 h after the initial treatment by in vivo imaging 
using the Xenogen IVIS system. Mice receiving intranasal pEGFP-N2 chitosan nanoparticles were included as positive control 
for in vivo imaging.
GFP siGLO
A
GFP   Naïve  siGLO C
GFP Naïve  siGLO BGenetic Vaccines and Therapy 2008, 6:7 http://www.gvt-journal.com/content/6/1/7
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ml) was measured 24 hrs after the final OVA challenge. It
was found that the siNPRA-treated mice had significantly
lower AHR than the OVA-positive control group or the
group receiving scrambled siNPRA (Fig. 3A).
Treatment with siNPRA and imiquimod cream reduced 
eosinophilia and lung pathology
The most direct indicator of airway inflammation is lung
histopathology. For the purpose of measuring the number
of eosinophils from animals of each group, BAL fluids
were collected and BAL cells were fixed on slides by cyto-
centrifugation and stained using a differential cell staining
kit. Eosinophils were counted microscopically and
expressed as percentage of total cells. Fig. 3B shows the
average eosinophil percentages from the four groups with
different treatments. It is obvious that topical treatment
with siNPRA nanoparticles mixed with imiquimod cream
reduced eosinophil recruitment in the lung in this group.
After H & E staining, lung sections from mice treated with
siNPRA and imiquimod cream showed a substantial
decrease in lung inflammation, goblet cell hyperplasia
and infiltration of inflammatory cells compared to the
untreated OVA group and the group treated with scram-
bled siRNA (Fig. 3C).
Treatment with siNPRA and imiquimod cream reduced IL-
4 and IL-5 levels
The pro-inflammatory cytokines IL-4 and IL-5 are biolog-
ical markers of airway inflammation. The levels of IL-4
and IL-5 were measured by ELISA or mouse Th1/Th2
Cytokine CBA kit following the manufacturer's instruc-
tion (BD Bioscience, CA). Significant reduction of IL-4
was observed in the siNPRA-treated group (Fig. 4A). IL-5
was also downregulated by siNPRA treatment (Fig. 4B).
However, there was no significant change in IL-2, INF-γ
and TNF-α when mice were treated with siNPRA nanopar-
ticles compared to the untreated group or scrambled
siRNA-treated group (Fig. 4B). Taken together, the
observed changes in inflammatory cytokines, AHR and
lung pathology demonstrate that siNPRA chitosan nano-
particles delivered through imiquimod cream can afford
significant protection from airway allergy and inflamma-
tion.
Discussion
Here we report that a topical cream containing siNPRA
and imiquimod modulates lung inflammation in a mouse
model of allergic asthma. Both imiquimod and siNPRA
showed anti-inflammatory effect in our test. However,
siNPRA was the dominant protective agent as evidenced
by comparison with the relatively low reduction in
inflammation in the scrambled siRNA-treated group in
which the protection resulted from imiquimod alone.
However, besides the anti-inflammatory effect of imiqui-
mod, the penetrating agent in the imiquimod cream also
facilitated the penetration siNPRA. To the best of our
knowledge, this is the first report of the transdermal deliv-
ery of synthetic siRNA.
Transdermal delivery of biomolecules and drugs has sev-
eral advantages over other delivery routes. First, it is pain-
less and therefore a boon to patients who require frequent
drug administration. Second, the cream is simple to apply
and particularly useful for treating asthmatic infants who
cannot be given drugs easily or safely by oral, intranasal or
inhalational routes. A transdermal cream to administer
the chitosan-conjugated nanocomplexes is expected to be
safe and effective and may have advantages over electro-
poration or particle-mediated epidermal delivery of DNA/
NPRA knockout prevents allergic airway inflammation Figure 2
NPRA knockout prevents allergic airway inflamma-
tion. (A) Knockout of NPRA but not NPRC attenuates air-
way inflammation. C57BL6 wild type, NPRA-/- and NPRC-/- 
knockout mice were OVA-sensitized (i.p.) at day zero and 
day seven and challenged twice with OVA (i.n.). Two days 
later, mice were sacrificed and lung sections were stained 
with hematoxylin/eosin. (B) BAL fluids were obtained from 
WT and NPRA-/- mice and assayed by ELISA for pro-inflam-
matory cytokines, IL-4, -5 and -6. Results shown are averages 
of two separate experiments with standard deviations (*, P < 
0.05, **, P < 0.01).Genetic Vaccines and Therapy 2008, 6:7 http://www.gvt-journal.com/content/6/1/7
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RNA in which transient skin irritation was observed
[24,25]. The capability of biocompatible chitosan nano-
particles for transdermal delivery of siRNA makes chi-
tosan a very promising agent for treating asthma and
other diseases especially in children. The nanocomplexa-
tion with chitosan may contribute to easier penetration of
siRNA through the outermost barriers of the skin and may
also provide longer duration of siRNA in vivo.
Our results suggest that the ANP-NPRA signaling pathway
plays an important role in inflammation of the airway
and that prevention and control of pathology could be
achieved by inhibition of ANP signaling. We found that
increased production of ANP induced airway inflamma-
tion in normal mice and augmented inflammation in a
murine model of allergen-induced asthma. NPRA-/- mice
exhibit significantly lower inflammation of the lung com-
pared to wild-type mice. This result is consistent with our
previous finding that NP73-102, an inhibitor of NPRA,
Treatment with siNPRA and imiquimod cream reduced allergic airway hyperreactivity, lung eosinophilia and pathology Figure 3
Treatment with siNPRA and imiquimod cream reduced allergic airway hyperreactivity, lung eosinophilia and 
pathology. (A) Transdermally-delivered siNPRA reduces airway hyperreactivity. Mice were sensitized to OVA, given the indi-
cated treatments and challenged with OVA intranasally. AHR to methacholine challenge was recorded 24 h later in a whole-
body plethysmograph which measures the enhanced pause (PENH). The PENH values for each methacholine concentration 
were averaged and expressed as a percentage of the PBS baseline reading. Results shown are averages of two separate experi-
ments with standard deviations (*, P < 0.05). (B) Decrease in eosinophil numbers by siNPRA-imiquimod treatment. BAL cells 
were air dried and stained with a modified Wright's stain. Total cell numbers were approximately the same in each group and 
the number of eosinophils is given as percentage of the total. Treatment by siNPRA-imiquimod cream significantly reduced 
eosinophils in the BAL compared to controls Results shown are averages of two separate experiments with standard devia-
tions (**, P < 0.01). (C) Reduction of lung inflammation by siNPRA-imiquimod cream. Lungs were removed, fixed in formalin 
and sectioned. Slides were stained with hematoxylin and eosin. Treatment with siNPRA caused a substantial decrease in lung 
inflammation, goblet cell hyperplasia and infiltration of inflammatory cells compared to the OVA control group and the group 
treated with scrambled siNPRA (scr-siNPRA) nanoparticles. Lung sections from naïve animals without any treatment show 
normal healthy lungs.Genetic Vaccines and Therapy 2008, 6:7 http://www.gvt-journal.com/content/6/1/7
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decreased several pro-inflammatory transcription factors
in the lung [15]. Increased airway inflammation is associ-
ated with activation of the transcription factors nuclear
factor-kappa B (NFκB) and activator protein-1 (AP1), and
the extracellular signal-regulated receptor kinase (Erk1/2).
ANP also reduces TNF-α-induced actin polymerization
and endothelial permeability and increases cytoprotective
proteins such as hemeoxygenase-1 [26]. In human lung
epithelial cells, intracellular expression of ANP together
with the synthetic natriuretic peptide, NP73-102,
decreased activation of NFκB, AP-1 and Erk 1, 2. NP73-
102 possesses anti-inflammatory activity and is capable of
preventing pulmonary inflammation when given prophy-
lactically or therapeutically. The evidence that NPRA-/-
mice have less eosinophilia and lower levels of Th2-like
cytokines compared to wild type indicate that the ANP
pathway is pro-Th2, and this is consistent with a previous
study which showed that human DCs exposed to ANP
promoted TH2-like cytokine expression.
Transdermally delivered siNPRA significantly decreased
lung inflammation in BALB/c mice as evident from lung
section staining, eosinophil counting and quantitation of
Th2-like cytokines IL-4 and IL-5. These results are in agree-
ment with the previous reports that activation of the ANP
pathway increases Th2 dominance. Also, siNPRA-treated
BALB/c mice exhibit significantly lower airway hyperre-
sponsiveness than those receiving scrambled siRNA. This
indicated that in addition to its anti-inflammatory activ-
ity, knockdown of NPRA by siNPRA also attenuates AHR
which operates through a different set of genes from the
inflammatory cytokines.
In summary, we demonstrate that synthetic chitosan-
siRNA nanocomplexes can be effectively delivered
transdermally. The lack of pulmonary inflammation in
mice deficient in NPRA or in mice treated by siNPRA pro-
vides compelling evidence for the role of ANP-NPRA sig-
naling in pulmonary inflammation. Moreover,
transdermally applied siNPRA chitosan nanoparticles
have proven safe and effective in mice and may provide an
innovative new treatment approach for preventing airway
inflammation and asthma in humans.
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Cytokine production in BALB/c mice is altered by siNPRA-imiquimod treatment Figure 4
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ured by IL-4 ELISA. Significant reduction of IL-4 was achieved by siNPRA-imiquimod treatment compared to OVA controls. 
(B) Lungs of all animals from the four groups were removed and homogenized. The levels of IL-2, IL-5, IFN-γ and TNFα in lung 
homogenates were measured using a mouse Th1/Th2 Cytokine CBA kit. IL-5 was significantly downregulated by siNPRA treat-
ment. Results shown are averages of two separate experiments with standard deviations (*, P < 0.05, **, P < 0.01).
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